Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the off...
Initiated U.S. ZTALMY ® (ganaxolone) launch in late July with over 50 completed CDKL5 deficiency disorder prescription enrollment forms; approximately 40% of those patients were on reimbursed therapy by the end of the third quarter ZTALMY generated $0.56 million in net pr...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is $0.02 (+103.8% Y/Y) and the consensus Revenue Estimate is $25.76M (+154.8% Y/Y). Over the last 1 year, MRNS...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5M upfront in return for payments based on U.S. net sales of ganaxolone, including the recently approved ZTALMY or...
$32.5 million upfront payment provides non-dilutive capital to further support commercialization of ZTALMY ® (ganaxolone); projected to extend cash runway into 2024 Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the developm...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s a scientific reality that people don’t operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out of the...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October. Details...
Summary Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA. ...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) said the Biomedical Advanced Research and Development Authority (BARDA) exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities for seizure therapy ganaxolone active pharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...